Compare Stocks: RARE, NUVL, HALO, and CYTK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$76.76 -5.7%	$78.91	$32.89 ▼ $88.31	$9.55B	0.38	1.73 million shs	3.60 million shs
HALO Halozyme Therapeutics	$103.12 +20.2%	$76.48	$61.22 ▼ $103.30	$12.23B	0.85	1.69 million shs	7.69 million shs
NUVL Nuvalent	$123.96	$119.84	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
RARE Ultragenyx Pharmaceutical	$25.91 +0.3%	$27.89	$18.29 ▼ $39.89	$2.55B	0.35	1.79 million shs	3.83 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-0.48%	-10.82%	-0.20%	+118.44%
HALO Halozyme Therapeutics	0.00%	+24.93%	+31.16%	+60.82%	+65.46%
NUVL Nuvalent	0.00%	0.00%	+0.10%	+17.74%	+60.51%
RARE Ultragenyx Pharmaceutical	0.00%	+4.01%	-25.14%	-0.80%	-7.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$76.76 -5.7%	$78.91	$32.89 ▼ $88.31	$9.55B	0.38	1.73 million shs	3.60 million shs
HALO Halozyme Therapeutics	$103.12 +20.2%	$76.48	$61.22 ▼ $103.30	$12.23B	0.85	1.69 million shs	7.69 million shs
NUVL Nuvalent	$123.96	$119.84	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
RARE Ultragenyx Pharmaceutical	$25.91 +0.3%	$27.89	$18.29 ▼ $39.89	$2.55B	0.35	1.79 million shs	3.83 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-0.48%	-10.82%	-0.20%	+118.44%
HALO Halozyme Therapeutics	0.00%	+24.93%	+31.16%	+60.82%	+65.46%
NUVL Nuvalent	0.00%	0.00%	+0.10%	+17.74%	+60.51%
RARE Ultragenyx Pharmaceutical	0.00%	+4.01%	-25.14%	-0.80%	-7.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.90	Moderate Buy	$100.85	31.38% Upside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-11.56% Downside
NUVL Nuvalent	2.15	Hold	$127.73	3.04% Upside
RARE Ultragenyx Pharmaceutical	2.83	Moderate Buy	$57.82	123.17% Upside

Current Analyst Ratings Breakdown

Latest RARE, NUVL, HALO, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	CYTK Cytokinetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$117.00 ➝ $112.00
8/7/2026	HALO Halozyme Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	CYTK Cytokinetics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	CYTK Cytokinetics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$105.00 ➝ $110.00
8/7/2026	CYTK Cytokinetics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$102.00 ➝ $112.00
8/7/2026	HALO Halozyme Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$96.00 ➝ $105.00
8/7/2026	HALO Halozyme Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$92.00 ➝ $93.00
8/7/2026	HALO Halozyme Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$75.00 ➝ $95.00
8/7/2026	HALO Halozyme Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$110.00
8/7/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$95.00 ➝ $115.00
8/5/2026	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$47.00 ➝ $45.00

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$67.67M	141.15	N/A	N/A	($5.39) per share	-14.24
HALO Halozyme Therapeutics	$1.40B	8.76	$4.77 per share	21.61	$0.42 per share	245.52
NUVL Nuvalent	N/A	N/A	N/A	N/A	$15.95 per share	N/A
RARE Ultragenyx Pharmaceutical	$673M	3.80	N/A	N/A	($0.83) per share	-31.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-56.07%	N/A
HALO Halozyme Therapeutics	$316.89M	$3.35	30.78	11.23	0.43	24.86%	232.11%	24.16%	N/A
NUVL Nuvalent	-$425.38M	-$6.06	N/A	N/A	N/A	N/A	-40.11%	-35.43%	N/A
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-43.78%	N/A

Latest RARE, NUVL, HALO, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million
5/11/2026	Q1 2026	HALO Halozyme Therapeutics	$1.54	$1.60	+$0.06	$1.22	$358.60 million	$376.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	4.21	4.21
HALO Halozyme Therapeutics	8.81	2.76	2.33
NUVL Nuvalent	N/A	16.14	16.14
RARE Ultragenyx Pharmaceutical	N/A	2.02	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
HALO Halozyme Therapeutics	97.79%
NUVL Nuvalent	97.26%
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.60%
HALO Halozyme Therapeutics	2.50%
NUVL Nuvalent	5.02%
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	124.43 million	121.20 million	Optionable
HALO Halozyme Therapeutics	390	118.61 million	115.65 million	Optionable
NUVL Nuvalent	40	79.00 million	75.03 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable

RARE, NUVL, HALO, and CYTK Headlines

Recent News About These Companies

Barclays Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)

58 minutes ago | theglobeandmail.com

Quantinno Capital Management LP Purchases 137,758 Shares of Ultragenyx Pharmaceutical Inc. $RARE

August 8 at 4:47 AM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to Hold at Wall Street Zen

August 8 at 1:49 AM | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Upgraded by Wall Street Zen

August 8 at 1:47 AM | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts

August 7 at 4:28 AM | marketbeat.com

Wells Fargo & Company Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

August 7 at 3:09 AM | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up After Strong Earnings

August 7 at 1:41 AM | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

August 6 at 10:26 PM | theglobeandmail.com

Ultragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmed

August 6 at 12:25 PM | finance.yahoo.com

Guggenheim Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

August 6 at 2:30 AM | americanbankingnews.com

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

August 5, 2026 | zacks.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $45.00 by Analysts at Wells Fargo & Company

August 5, 2026 | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up on Strong Earnings

August 5, 2026 | marketbeat.com

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

August 4, 2026 | marketbeat.com

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

August 4, 2026 | zacks.com

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

August 4, 2026 | zacks.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Posts Earnings Results, Beats Estimates By $0.32 EPS

August 4, 2026 | marketbeat.com

Ultragenyx: Q2 Earnings Snapshot

August 4, 2026 | aol.comA

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

August 4, 2026 | globenewswire.com

Guggenheim Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

August 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RARE, NUVL, HALO, and CYTK Company Descriptions

Cytokinetics NASDAQ:CYTK

$76.76 -4.61 (-5.67%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$77.52 +0.76 (+0.99%)

As of 08/7/2026 07:58 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Halozyme Therapeutics NASDAQ:HALO

$103.12 +17.36 (+20.24%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$101.25 -1.87 (-1.82%)

As of 08/7/2026 07:56 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Nuvalent NASDAQ:NUVL

$123.96 0.00 (0.00%)

As of 07/16/2026

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Ultragenyx Pharmaceutical NASDAQ:RARE

$25.91 +0.09 (+0.35%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$26.02 +0.11 (+0.42%)

As of 08/7/2026 07:34 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RARE, NUVL, HALO, and CYTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RARE, NUVL, HALO, and CYTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RARE, NUVL, HALO, and CYTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RARE, NUVL, HALO, and CYTK Company Descriptions

Cytokinetics NASDAQ:CYTK

Halozyme Therapeutics NASDAQ:HALO

Nuvalent NASDAQ:NUVL

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RARE, NUVL, HALO, and CYTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RARE, NUVL, HALO, and CYTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RARE, NUVL, HALO, and CYTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RARE, NUVL, HALO, and CYTK Company Descriptions

Cytokinetics NASDAQ:CYTK

Halozyme Therapeutics NASDAQ:HALO

Nuvalent NASDAQ:NUVL

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools